Floatz logo

Gene-Modified Cd34+ Cells

Fanconi's Anemia

National Heart, Lung, and Blood Institute (NHLBI)Cell therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Fanconi's Anemia cohort.

Asset / SponsorPhaseRating
Anti-Thymoglobulin, Rabbit
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2B
Amifostine
Dana-Farber Cancer Institute
Phase 1CC
FACC retroviral vector
University of Minnesota
Phase 1CC
Clofarabine
University of California, San Francisco
D
ETOPOSIDE
University of California, San Francisco
D

Same molecule, other indications

Gene-Modified Cd34+ Cells is also rated in:

PancytopeniaDormant
CC
Indicative ·
47 / 100
View asset →
sickle cell diseaseDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →